Why Delay Sublocade™? Experiences with Inpatient Buprenorphine ER Injections

May 25, 2023
2:00 p.m.–3:00 p.m. ET

Hosted by the Substance Use Disorder SIG

Sublocade™ (buprenorphine ER subcutaneous injection) is currently FDA approved for opioid use disorder following 7 days of a transmucosal buprenorphine product. For opioid use disorder (OUD) patients admitted to the hospital, discussing OUD management and providing a long acting management option prior to discharge may help increase medication assisted therapy clinic retention rates. However, implementing such a program has several potential barriers.


  1. Describe potential benefits of administering inpatient buprenorphine ER injections
  2. Identify potential challenges of administering inpatient buprenorphine ER injections


Andrew Merker
Associate Professor
Midwestern University College of Pharmacy Downers Grove



Register Me